{"id":1925,"date":"2020-07-08T20:26:33","date_gmt":"2020-07-08T20:26:33","guid":{"rendered":"http:\/\/brief.euretina.org\/?p=1925"},"modified":"2021-03-17T14:38:43","modified_gmt":"2021-03-17T14:38:43","slug":"largest-study-of-visual-field-vf-progression-for-rp-aims-to-reporting-three-goldmann-targets-v4e-iii4e-and-i4e","status":"publish","type":"resource","link":"https:\/\/euretina.org\/resource\/largest-study-of-visual-field-vf-progression-for-rp-aims-to-reporting-three-goldmann-targets-v4e-iii4e-and-i4e\/","title":{"rendered":"Largest study of visual field (VF) progression for RP aims to reporting three Goldmann targets (V4e, III4e and I4e) \u00a0"},"content":{"rendered":"<p>A new study from the University of Alberta has been reported <span lang=\"EN-GB\">to be among the largest study to evaluate the entire Goldmann visual field area of retinitis pigmentosa (RP) patients, comparing different target sizes and inheritance patterns.\u00a0 The study recorded long follow-up times evaluating the long-term natural course of visual field (VF) in an RP population.\u00a0 The researchers were aiming to providing more \u201cspecific advice for patients who commonly ask about the expected rate of vision loss\u201d.\u00a0 The Goldmann visual field (GVF), measuring three different targets (V4e, III4e, and I4e), recorded 275 kinetic VF tests collected from 52 subjects with RP over a period of up to 29 years.<\/span><\/p>\n<p><span lang=\"EN-GB\">\u00a0<\/span><\/p>\n<p>RP is a group of hereditary retinopathies affecting approximately 1 in 3,500 people in the developed world.\u00a0 The disorders are characterised by the early onset of night blindness followed by a progressive loss of the visual field.\u00a0 The primary defect underlying RP affects the rod photoreceptor cell population and subsequently, molecular and cellular mechanisms trigger the apoptotic degeneration of both rod and cone photoreceptors.\u00a0 A further major characteristic of this group of disorders is the genetic and clinical heterogeneity which has complicated the developments of therapeutic strategies aimed at slowing or halting photoreceptor cell death.\u00a0 In the current Canadian study, researchers <span lang=\"EN-GB\">grouped their RP cohort into different inheritance patterns which showed that the mean rate of visual field loss was estimated to be 10.3% (P = 0.009) for autosomal recessive, an estimated 2.7% (P = 0.215) for autosomal dominant, and finally, an estimated 7.2% (P= 0.009) for X-linked inheritance, although the differences among them were not statistically significant (P &gt; 0.05).\u00a0 Inheritance patterns included autosomal recessive (n = 32), autosomal dominant (n = 5), and X-linked (n = 15).<\/span><\/p>\n<p><span lang=\"EN-GB\">\u00a0<\/span><\/p>\n<p><span lang=\"EN-GB\">The research study found that there was a significant interocular correlation in both visual acuity (VA) (R2 =0.739, P &lt; 0.001) and VF area (R2 = 0.815, P &lt; 0.001), while the annual rates of decline in VF area for V4e, III4e, and I4e targets were 7.5%, 10.7%, and 12.5%, respectively (all P &lt; 0.001). The study reported that all of the rates were significantly different from each other (P &lt; 0.001). \u00a0\u00a0The average follow-up time was 12 years (median, 10 years; range, 2\u201329 years). \u00a0Based on visual field, the analysis showed that, \u201cour patients failed the driving standard and reached legal blindness at a median ages of 37 years (95% CI, 30\u201344) and 55 years (95% CI, 49\u201361), respectively, with a significant difference between these two survival distributions (P &lt; 0.001).\u00a0 In conclusion of their study the researchers commented that, \u201cthe deterioration in visual acuity and visual field area is highly correlated between two eyes in patients with RP, the rate of VF loss varies among target sizes, and 50% of RP patients are not qualified to drive by the age of 37 and become legally blind by the age of 55. Our results can be useful not only in counseling patients with RP as to their potential rate of visual field loss but also in guiding healthcare professionals on screening regarding patients\u2019 medical fitness to drive\u201d.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new study from the University of Alberta has been reported to be among the largest study to evaluate the entire Goldmann visual field area of retinitis pigmentosa (RP) patients, comparing different target sizes and inheritance patterns.\u00a0 The study recorded long follow-up times evaluating the long-term natural course of visual field (VF) in an RP [&#8230;]\n","protected":false},"author":2,"featured_media":75643,"template":"","categories":[86,70],"tags":[179],"session_type":[],"event":[],"subject_disease":[],"section":[],"speaker":[],"resource_type":[199],"acf":[],"_links":{"self":[{"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/resource\/1925"}],"collection":[{"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/resource"}],"about":[{"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/types\/resource"}],"author":[{"embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":1,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/resource\/1925\/revisions"}],"predecessor-version":[{"id":2325,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/resource\/1925\/revisions\/2325"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/media\/75643"}],"wp:attachment":[{"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/media?parent=1925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/categories?post=1925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/tags?post=1925"},{"taxonomy":"session_type","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/session_type?post=1925"},{"taxonomy":"event","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/event?post=1925"},{"taxonomy":"subject_disease","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/subject_disease?post=1925"},{"taxonomy":"section","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/section?post=1925"},{"taxonomy":"speaker","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/speaker?post=1925"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/euretina.org\/wp-json\/wp\/v2\/resource_type?post=1925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}